THU0432 Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase III, Randomized, Controlled TrialsArthur Kavanaugh, P. J. Mease, Lichen Teng et al.|Annals of the Rheumatic Diseases|2016Cited by 6
POS1048 SAFETY AND EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM A RANDOMISED PHASE 2 TRIALP. J. Mease, Sibabrata Banerjee, M. Nys et al.|Annals of the Rheumatic Diseases|2022Cited by 5
SAT0436 Durability of apremilast response in patients with psoriatic arthritis: long-term (208-week) results from the palace 1 trialArthur Kavanaugh, J. Wollenhaupt, Gladman Dd et al.|Annals of the Rheumatic Diseases|2017Cited by 0